Cargando…

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

BACKGROUND: Naltrexone is an effective medication for treatment of alcohol dependence, but its efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of naltrexone may increase adherence. METHODS: A single site, 6-week open label study was conducted with 16...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galloway, Gantt P, Koch, Monika, Cello, Ryan, Smith, David E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087493/ https://www.ncbi.nlm.nih.gov/pubmed/15804355 http://dx.doi.org/10.1186/1471-244X-5-18

Ejemplares similares

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone
por: Colquhoun, Ross M.
Publicado: (2013)

Naltrexone long-acting formulation in the treatment of alcohol dependence
por: Johnson, Bankole A
Publicado: (2007)

Naltrexone and the Treatment of Alcohol Dependence
por: Volpicelli, Joseph R., et al.
Publicado: (1994)

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022)

An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
por: Vijayakumar, Jayanthi, et al.
Publicado: (2022)

Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease
por: Ayyala, Divya, et al.
Publicado: (2022)

Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans
por: Leighty, Anne E., et al.
Publicado: (2019)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
por: Naderer, Odin, et al.
Publicado: (2015)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis
por: Devereux, Graham, et al.
Publicado: (2016)

Amyloid as a Depot for the Formulation of Long-Acting Drugs
por: Maji, Samir K, et al.
Publicado: (2008)

Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2019)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients
por: Shore, Neal, et al.
Publicado: (2019)

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
por: Anderson, G., et al.
Publicado: (2010)

Views about responsibility for alcohol addiction and negative evaluations of naltrexone
por: Johnson, Rebecca A, et al.
Publicado: (2015)

Naltrexone ameliorates functional network abnormalities in alcohol‐dependent individuals
por: Morris, Laurel S., et al.
Publicado: (2017)

Naltrexone-induced psychosis in a patient with alcohol use disorder
por: Ruei-Yuan, Hu, et al.
Publicado: (2023)

Open Label Trial of the Tolerability and Efficacy of Zonisamide in the Treatment of Alcohol Dependence
por: Knapp, Clifford M., et al.
Publicado: (2010)

A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence
por: Kumar, Arun, et al.
Publicado: (2020)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
por: Asahina, Hajime, et al.
Publicado: (2012)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Venom immunotherapy: safety and tolerability of the build‐up phase with depot versus aqueous preparations
por: Pravettoni, Valerio, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study
por: Trivedi, Ashit, et al.
Publicado: (2022)

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
por: Hamel, Remi K, et al.
Publicado: (2023)

A randomized trial: The safety, pharmacokinetics and preliminary pharmacodynamics of ropivacaine oil delivery depot in healthy subjects
por: Lu, Wu-dang, et al.
Publicado: (2023)

Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs
por: Blizzard, Charles, et al.
Publicado: (2016)

Predictors of Interest in an Alcohol Reduction Clinical Trial of Naltrexone among Undergraduates
por: Leeman, Robert F, et al.
Publicado: (2013)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
por: Trivedi, Ashit, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
por: van Rossem, Koen, et al.
Publicado: (2013)

Safety, tolerability, and pharmacokinetics of 6-month daily dosing of an oral formulation of cyclosporine (ATOPICA for cats®) in cats
por: Roberts, E S, et al.
Publicado: (2014)

O-Benzoylnaltrexone
por: Yang, Rui, et al.
Publicado: (2013)

Asymmetric synthesis of (–)-naltrexone
por: Dongbang, Sun, et al.
Publicado: (2018)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Injectable Lipid-Based Depot Formulations: Where Do We Stand?
por: Rahnfeld, Lisa, et al.
Publicado: (2020)

Selection of 12‐Hour Sustained‐Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained‐Release Prototype Formulations and Standard Acetaminophen Formulation: An Open‐Label, Randomized, Proof‐of‐Principle Pharmacokinetic Study
por: Yue, Yong, et al.
Publicado: (2017)

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study
por: Hong, Ruoxi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3lt57vp8cmms7dmqf07bjav536